VolitionRX (VNRX) AI Stock Analysis

• Market Cap: $31.44M
• Dividend Yield: N/A
• Average Volume (3M): 995.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: 14.48%
• EPS Growth: 36.83%
• Country: US
• Employees: 85
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 122,801,575
• 10 Day Avg. Volume: 825,693
• 30 Day Avg. Volume: 995,625
• PEG Ratio: 0.05
• Price to Book (P/B): -2.08
• Price to Sales (P/S): 42.09
• P/FCF Ratio: -1.96
• Enterprise Value/Market Cap: 2.65
• Enterprise Value/Revenue: 56.52
• Enterprise Value/Gross Profit: 56.52
• Enterprise Value/Ebitda: -4.11
• 1Y Price Target: $2.50
• Price Target Upside: 455.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.29 ▼(-36.44% Downside)

VolitionRX's overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. The technical analysis also indicates bearish momentum, further weighing down the score. While the earnings call provided some positive insights into strategic partnerships and revenue growth, these factors are not enough to offset the significant financial and technical challenges.

VolitionRX Business Overview & Revenue Model

Company Description

VolitionRX (VNRX) is a biotechnology company focused on developing and commercializing innovative blood-based diagnostic tests for various cancers. The company operates primarily in the healthcare sector, leveraging its proprietary Nucleosomics technology to detect cancer through the analysis of nucleosomes—DNA fragments released by dying cells. VolitionRX aims to improve early cancer detection, thereby increasing treatment success rates and potentially saving lives with its core products designed for clinical use.

How the Company Makes Money

VolitionRX generates revenue primarily through the commercialization of its cancer diagnostic tests, which are sold to laboratories and healthcare providers. The company has established partnerships with various laboratories and healthcare institutions to facilitate the adoption of its tests in clinical settings. Additionally, VolitionRX may receive funding through grants and collaborations with research organizations or pharmaceutical companies, further supporting its product development and market expansion efforts. The revenue model is centered on test sales, with potential for recurring revenue as more healthcare providers adopt their diagnostics.

VolitionRX Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

VolitionRX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNRX, the sentiment is Negative. The current price of 0.45 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.36, and below the 200-day MA of 0.54, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 43.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNRX.

VolitionRX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
PRPO	57 Neutral	$38.88M	-27.67	-9.76%	―	30.95%	59.67%
BNR	57 Neutral	$233.64M	-14.55	-19.87%	―	5.44%	72.17%
BDSX	51 Neutral	$53.22M	-1.27	-302.55%	―	22.29%	31.93%
VNRX	42 Neutral	$31.44M	-1.17	―	―	14.48%	36.83%
TRIB	40 Underperform	$16.25M	-0.31	―	―	-4.35%	-6.31%
BNGO	40 Underperform	$16.28M	-0.10	-78.22%	―	-13.84%	88.80%

VolitionRX Corporate Events

VolitionRX Amends Underwriting Agreement for Stock Offering

On October 10, 2025, VolitionRx Limited entered into an Underwriting Agreement with Newbridge Securities Corporation for a public offering of 11,550,000 shares of common stock, along with warrants for an equal number of shares. The offering was priced at $0.52 per share, including a $0.01 warrant, with a 7% underwriting discount. On November 7, 2025, an amendment to the agreement allowed the underwriter to exercise an over-allotment option for 1,194,000 shares and 1,732,500 warrants at the same price, enhancing flexibility in the offering.